Linked Life Data

3966006

Source:http://linkedlifedata.com/resource/pubmed/id/3966006

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1985-2-5
pubmed:abstractText
We treated 12 patients with Parkinson's disease with an 8-alpha-amino-ergoline derivative, CU 32-085. The daily dosage was increased slowly to 7 mg over 9 weeks, held constant for 8 weeks, then replaced by placebo for 4 weeks. We found statistically significant benefit over placebo or pretreatment disability. The effect was seen at daily dosages of 3 mg or more. Its magnitude was dose related. There was no further improvement on prolonged treatment with 7 mg daily. Side effects were mild and did not require interruption of treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0028-3878
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
83-7
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
Initial treatment of parkinsonism with 8-alpha-amino-ergoline.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't